Pneumocystis jirovecii

• Opportunistic fungal infection of the lower respiratory infection

Microbiology

• Yeast-like fungus in the Ascomycota phylum
• Has not been able to be grown in culture, and species within the genus have tropism for their specific host
• It's cell wall lacks ergosterol, so has inherent resistance to many antifungals
• β-1,3 glucan, however, is an important cell wall component
• The major immunogenic protein is major surface glycoprotein (Msg), or gpA

History

• P. jirovecii was previously thought to be P. carinii, but it was later realized that they were two species within the same genus
  • P. carinii and P. wakefieldiae infect rats, P. murina infects mice and P. jiroveci infects humans
• Also previously thought to be a protozoan, but reclassified as fungus based on phylogenetic analysis, most closely related to Schizosaccharomyces pombe

Epidemiology

• Worldwide distribution
• Only circulates within humans
• Most children have been exposed by age 2 or 3
• Children and immunocompromised patients being the reservoir
  • Includes asymptomatic carriage by patients with HIV, malignancy, and long-term steroid use, and in pregnant women
• Risk factors for infection:
  • HIV
  • Immune-suppression, e.g. from steroids

Pathophysiology

• After inhalation of cyst, trophic forms are released and adhere to type I pneumocytes in the alveolar epithelium
• The immune response involves a combination of humoral and cell-mediated immunity
  • Alveolar macrophages are the first response, but require CD4 cells to respond fully
  • IgM antibodies recognize common fungal carbohydrate antigens
  • CD4 cells are important for the memory response
• The alveolus fills with Pneumocystis
• The inflammatory response may damage the lung

Clinical Presentation

Infants

• Interstitial plasma cell pneumonia between 6 weeks and 4 months
• Typically in orphanages under crowded conditions
• Insidious onset with poor feeding, progressing to cyanosis

Adults

• Worsening exertional dyspnea, fever, and non-productive cough
  • Symptoms usually more insidious in severe HIV
  • Symptoms may develop after tapering immunosupressive drugs like steroids
• Tachypnea and tachycardia with exertional hypoxemia
• CXR may initially be normal, then progresses to whiteout
  • Can also show unilateral consolidation, nodules, cysts, pneumatoceles, mediastinal lymphadenopathy, and pleural effusions
• High LDH from lung damage
• In advanced HIV, can disseminate to lymph nodes, spleen, liver, bone marrow, GI tract, eyes, thyroid, adrenal glands, and kidneys

Investigations

• CXR
• Typical: bilateral diffuse patchy disease
• Atypical:
  • Normal (15%)
  • Localized
  • Pneumothorax
  • Upper lobe, if on pentamidine
• LDH increased
• CBC often normal

Diagnosis

• Induced sputum or brochoalveolar lavage (normal sputum not sensitive enough)
• 6min walk test: will desaturate, even if well-oxygenated at rest

Treatment

• First-line: TMP-SMX 15-20 mg/kg IV or PO divided q6-8h
  • If mild-moderate, can give TMP-SMX DS 2 tabs PO tid
• Alternatives:
  • Clindamycin 600-900 mg IV q6-8h with primaquine 15 to 30 mg PO daily
  • Pentamidine 4 mg/kg IV daily
  • Trimethoprim 15 mg/kg PO divided q8h with dapsone 100 mg PO daily
  • Atovaquone 750 mg PO bid (for mild-moderate only)
• Adjunctive: Prednisone 40 mg PO bid for 5 days, followed by 40 mg PO daily for 5 days, followed by 20 mg po daily for 11 days
  • Can use methylprednisolone at 75% of predisone dose
  • Typically indicated if PaO₂ ≤70 mmHg or A-a O₂ gradient >35 mmHg
• Duration is 21 days (3 weeks)

Prophylaxis

• Indications
  • Medications: prenisolone ≥20 mg daily for >4 weeks; TNF-α inhibitors; steroids plus a steroid-sparing agent
  • Cancer treatment: steroids and cyclophosphamide; alemtuzumab for at least 2 months after treatment and until CD4 >200; temozolomide and radiation therapy, until CD4 >200; fludarabine and T-cell depletion, until CD4 >200; any antileukemic therapy
  • HIV: prior Pneumocystis pneumonia; CD4 <200; oropharyngeal Candida regardless of CD4
  • Rheumatology treatment: GPA receiving cyclophosphamide, especially with steroids
  • Transplantation: allogeneic stem cell transplantation for at least 180 days; autologous stem cell transplantation for at least 3 to 6 months
  • Primary immunodeficiency: SCID; idiopathic CD4 lymphocytopenia; hyper-IgM syndrome
• First-line: TMP-SMX DS or SS 1 tab PO daily
• Alternatives:
  • TMP-SMX DS 1 tab po tiw
  • Dapsone 100 mg po daily, or 50 mg po bid
  • Dapsone 50 mg po daily with pyrimethamine 50 mg po weekly and leucovorin 25 mg po weekly
  • Pentamidine 300 mg inhaled monthly
  • Atovaquone 750 mg po bid or 1500 mg po daily
  • Atovaquone as above with pyrimethamine 25 mg po daily and leucovorin 10 mg po daily
• Usually instituted if the risk of PJP is greater than 3.5% per year